Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$1.17M-$1.17MderivedN/M vs Q4 2022 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$1,273,266N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
Operating Cash Flowderived-$697,706N/M ended Dec 31, 2023 · filed Mar 29, 2024 · 89 d after period end